Shopping Cart
Remove All
Your shopping cart is currently empty
Vixarelimab (Synonyms: RO-7622888, RG-6536, KPL-716)
Catalog No. T76956 Copy Product Info
🥰Excellent
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis.
Vixarelimab
Copy Product Info🥰Excellent
Catalog No. T76956
Synonyms RO-7622888, RG-6536, KPL-716
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis.
Cas No. 2243320-83-2
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $372 | In Stock | In Stock | |
| 5 mg | $997 | - | In Stock | |
| 10 mg | $1,590 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.5% (SDS-PAGE); 97.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis. |
| In vitro | At a concentration of 0.0001 μg/mL, Vixarelimab (KPL-716) induces an increase in MCP-1/CCL2 levels in human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF). However, at concentrations of 0.001 μg/mL or higher, there is a significant decrease in MCP-1/CCL2 levels in both cell types[1]. Pre-treatment with Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) reduces MCP-1/CCL2 levels in both HEK and HDF cells induced by Oncostatin M (OSM) and OSM + IL-4. The maximum effect is observed at concentrations of 0.01 μg/mL and 0.1 μg/mL[1]. |
| Synonyms | RO-7622888, RG-6536, KPL-716 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | OSMR |
| Molecular Weight | 144.99 kDa |
| Cas No. | 2243320-83-2 |
| Isotype | IgG4 (S228P) |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Vixarelimab | purchase Vixarelimab | Vixarelimab cost | order Vixarelimab | Vixarelimab chemical structure | Vixarelimab in vitro | Vixarelimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.